Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials, Neurology, vol.76, issue.1, pp.14-25, 2011. ,
Trends in survival and cause of death in Danish patients with multiple sclerosis, Brain, vol.127, pp.844-50, 2004. ,
Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, issue.20, pp.1430-1438, 2000. ,
Evaluating the safety of beta-interferons in MS: A series of nested case-control studies, Neurology, 2017. ,
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases, J Clin Epidemiol, vol.45, issue.6, pp.613-622, 1992. ,
Interferon-beta mechanisms of action in multiple sclerosis, Neurology, vol.74, issue.1, pp.17-24, 2010. ,
Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure, BMC Med Res Methodol, vol.5, issue.1, p.5, 2005. ,
, Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis, European Study Group on Interferon B-1b in Secondary Progressive MS, vol.352, pp.1491-1498, 1998.
Association between beta-interferon exposure and hospital events in multiple sclerosis, Pharmacoepidemiol Drug Saf, vol.23, issue.11, pp.1213-1235, 2014. ,
Long-term follow-up of clinical trials of multiple sclerosis therapies, Neurology, vol.76, issue.1, pp.26-34, 2011. ,
Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures, J Gen Virol, vol.81, pp.2341-64, 2000. ,
Causes of death among commercially insured multiple sclerosis patients in the United States, PLoS One, 2014. ,
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNbeta-1b study, BMJ Open, vol.2, issue.6, 2012. ,
Evidence-based medicine: promise and pitfalls, Mult Scler, vol.18, issue.7, 2012. ,
Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial, Neurology, vol.78, pp.1315-1337, 2012. ,
The AAN response to evidence-based medicine: promise and pitfalls ,
, Mult Scler, vol.18, issue.7, pp.949-50, 2012.
Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway, Mult Scler, vol.14, issue.9, 2008. ,
, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. The IFNB Multiple Sclerosis Study Group, Neurology, vol.43, issue.4, pp.655-61, 1993.
,
, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG), Ann Neurol, vol.39, issue.3, pp.285-94, 1996.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, vol.45, issue.7, pp.1268-76, 1995. ,
A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting ,
, Eur J Neurol, vol.13, issue.1, pp.61-71, 2006.
Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada, J Neurol Neurosurg Psychiatry, vol.83, issue.1, pp.61-67, 2012. ,
Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry, J Neurol Neurosurg Psychiatry, vol.65, issue.1, pp.56-65, 1998. ,
Long-term survival of patients with multiple sclerosis in West France, Mult Scler, vol.13, issue.7, pp.865-74, 2007. ,
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study, PLoS One, vol.10, issue.7, p.132033, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01201656
Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study, J Neurol Neurosurg Psychiatry, vol.88, issue.8, 2017. ,
Effect of comorbidity on mortality in multiple sclerosis, Neurology, vol.85, issue.3, pp.240-247, 2015. ,
Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in More and Romsdal, Norway, J Neurol Neurosurg Psychiatry, vol.58, issue.4, pp.417-438, 1995. ,
, Multiple Sclerosis International Federation. Atlas of MS, 2013.
,
, PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis, Lancet, vol.352, issue.9139, pp.1498-504, 1998.
,
, Mortality and Cause of Death in Multiple Sclerosis: Findings from a Prospective PopulationBased Cohort in Bizkaia, Neuroepidemiology, vol.42, issue.4, pp.219-244, 2014.
Cause of death in patients attending multiple sclerosis clinics, Neurology, vol.41, issue.8, pp.1193-1199, 1991. ,
Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS, Neurol Clin Pract, vol.6, issue.5, pp.397-408, 2016. ,
Mortality in patients with multiple sclerosis, Neurology, vol.81, issue.2, pp.184-92, 2013. ,
, Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS Study Group, Neurology, vol.56, issue.11, pp.1496-504, 2001.
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis, Mult Scler Relat Disord, vol.6, pp.57-63, 2016. ,
Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients, Mult Scler, vol.15, issue.11, pp.1263-70, 2009. ,
Can we measure long-term treatment effects in multiple sclerosis?, Nat Rev Neurol, vol.11, issue.3, pp.176-82, 2015. ,
Immortal time bias in pharmaco-epidemiology, Am J Epidemiol, vol.167, issue.4, pp.492-501, 2008. ,
Causes of death among patients with multiple sclerosis, Mult Scler, vol.16, issue.12, pp.1437-1479, 2010. ,
Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group, Neurology, 1999. ,
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis ,
, Cochrane Database Syst Rev, vol.2015, issue.9, p.11381
Impact of multiple sclerosis relapses on progression diminishes with time, Neurology, vol.73, issue.20, pp.1616-1639, 2009. ,
Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, Clin Drug Investig, vol.33, issue.9, pp.647-52, 1997. ,
The multiple sclerosis market, Nat Rev Drug Discov, 2017. ,
, Vital Statistics Deaths. V2. Population Data BC, 2015.
, British Columbia Ministry of Health, PharmaNet. V2. 2015a Available from, 2015.
, Consolidation File (MSP Registration & Premium Billing). V2. Population Data BC, Data Extract MOH. 2015a Available from, 2015.
, British Columbia Ministry of Health [creator, 2015.
, Discharge Abstract Database (Hospital Separations). V2. Popualtion Data BC
, , 2015.
, British Columbia Ministry of Health [creator, 2015.
, Medical Services Plan (MSP) Payment Information File: Population Data BC
, , 2015.
Long-term survival of patients with multiple sclerosis in West France, Mult Scler, vol.13, issue.7, pp.865-74, 2007. ,
,
, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, vol.50, issue.1, pp.121-128, 2001.
New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, vol.13, issue.3, pp.227-258, 1983. ,
New perspectives in the natural history of multiple sclerosis, Neurology, vol.74, issue.24, pp.2004-2019, 2010. ,